Drug Trial Radar · NCT07948408
A Phase III Study of WSD0922-FU Versus Chemotherapy In Patients With C797S+ Advanced Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
196
Planned (sponsor's estimate)
Start
Dec 10, 2026
Primary completion
May 1, 2028
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- Wayshine Biopharm, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an Open-label, Randomized, Controlled, Multicenter Phase III Study Evaluating Efficacy and Safety of WSD0922-FU Monotherapy versus Platinum-based Doublet Chemotherapy for Participants with EGFR C797S Mutation-positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease have Developed Resistance to Prior First-line Third-generation EGFR-TKI Therapy
Conditions
- Non Small Cell Lung Cancer (NSCLC)
Interventions
WSD0922-FUDrug
Participants will take WSD0922-FU 120 mg BID under fasted condition, administered orally; treatment cycles are 21 days in duration, continuing until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Platinum-based doublet chemotherapy (Pemetrexed and Cisplatin or Carboplatin)Drug
Participants will receive 4 cycles of standard platinum-based doublet chemotherapy (selected by the investigator based on participant's condition and tolerance): Option 1: Pemetrexed 500 mg/m² IV infusion + Cisplatin 75 mg/m² IV infusion on Day 1 of each 21-day cycle. Option 2: Pemetrexed 500 mg/m² IV infusion + Carboplatin AUC 5 IV infusion on Day 1 of each 21-day cycle. Followed by maintenace of Pemetrexed 500 mg/m² IV infusion until disease progression, occurrence of intolerable toxicity, withdrawal of informed consent, death, or fulfillment of other protocol-specified criteria for treatment discontinuation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From date of randomization until the date of BICR confirmed progression or date of death from any cause, whichever comes first, assessed up to 24 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.